StockData
Madrigal Pharmaceuticals, Inc. logo

Madrigal Pharmaceuticals, Inc. (MDGL) company profile

MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)

Close on Nov 17, 2026Market cap $9.75BP/E –Yield –

About Madrigal Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

The company is a biopharmaceutical enterprise dedicated to developing and commercializing therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), an inflammatory liver condition that causes progressive scarring and organ impairment. Its principal commercial offering is Rezdiffra (resmetirom), an oral thyroid hormone receptor beta agonist taken once daily to address liver fat accumulation and fibrosis. In addition, the firm advances a clinical pipeline that includes glucagon-like peptide-1 receptor agonists, diacylglycerol O-acyltransferase 2 inhibitors, and small interfering RNA programs designed to address complementary metabolic and genetic pathways of liver disease. Its treatments target adult patients diagnosed with noncirrhotic MASH who exhibit moderate to advanced liver fibrosis.

Commercial operations are active in the United States and Germany, where the company launched its core pharmaceutical product following regulatory clearances. It is also preparing for broader distribution across member states of the European Union and other international regions through direct filings or third-party distribution partnerships. The provided excerpt does not disclose the location of the corporate headquarters.

Summary of the business section of Madrigal Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Madrigal Pharmaceuticals, Inc.
Founded
2016
Headquarters
West Conshohocken, PA
Address
1001 Conshohocken State Road, Suite 2-350
Phone
(267) 824-2827
Employees
915, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania

Stock & identifiers

Ticker
MDGL
Exchange
Nasdaq
IPO date
Feb 6, 2007
Shares outstanding
23M, Jul 27, 2026
Public float
$5.60B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-43 reverse, Mar 31, 2017; 1-for-35 reverse, Jul 25, 2016
SEC CIK
1157601
CUSIP
558868105
ISIN
US5588681057
FIGI
BBG000QS6NV8
Share class FIGI
BBG001SNKQ42
LEI
549300CHIMT2EUSNJB60
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
William John SiboldPresident and CEO, Director202,801
Shannon T. KelleyGeneral Counsel10,397
David SoergelChief Medical Officer10,033
Carole HuntsmanChief Commercial Officer12,692
Mardi DierEVP and CFO12,850
Rita ThakkarChief Accounting Officer2,398
Robert E. WaltermireSenior VP, Chief Pharma Dev.10,918
667, L.P.Director1,669,016
Bros. Advisors Lp BakerDirector2,040,682
Julian BakerDirector1,612,339
Felix BakerDirector1,843,469
Brothers Life Sciences LP BakerDirector1,948,876
Bros. Advisors (GP) LLC BakerDirector1,947,968
John C. ReedDirector647
Daniel J. BrennanDirector1,371
Rebecca TaubDirector1,108,207
Jacqualyn A. FouseDirector1,551
Richard S. LevyDirector22,469
James M. DalyDirector3,081
Paul A. FriedmanDirector855,884
Kenneth BateDirector8,896
Fred B. CravesDirector390,028

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$19.21M$84.10M$6.55M$524$125
FY2024$12.21M$30.73M$5.47M$278$93
FY2023
Bill Sibold
$32.27M$42.28M$5.59M$208$94
FY2023
Paul A.Friedman
$9.56M-$29.11M$5.59M$208$94
FY2023
Paul A.Friedman M.D.
$9.56M$2.37M$5.59M$208$94
FY2023
Paul AFriedman
$9.56M$2.37M$5.59M$208$94

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Bill Sibold
President and Chief Executive Officer
$918.53K–$12.30M$4.54M$1.44M$14.00K$19.21M+57%
Mardi Dier
Executive Vice President and Chief Financial Officer
$566.04K–$3.56M$1.31M$554.17K$89.35K$6.09M-30%
David Soergel, M.D.
Executive Vice President and Chief Medical Officer
$418.18K$75.00K$5.91M$2.20M$584.10K–$9.19M–
Carole Huntsman
Executive Vice President and Chief Commercial Officer
$540.31K–$3.19M$1.18M$528.98K$9.84K$5.44M+38%
Shannon Kelley
Executive Vice President and Chief Legal Counsel
$535.17K–$3.00M$1.11M$523.94K$14.00K$5.18M+11%
Rebecca Taub, M.D.
Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
$617.50K–$4.12M$1.52M$604.54K–$6.87M+15%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 915 full-time employees, including 258 engaged in research, development and medical affairs, 526 in commercial activities and 131 in general and administrative functions.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 30, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Aug 1, 2016Name changeName changed from SYNTA PHARMACEUTICALS CORP to MADRIGAL PHARMACEUTICALS, INC.
Jul 22, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 22, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 8, 2016Merger voteDefinitive merger proxy statement
Dec 9, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 17, 2009Late filingNotification of late filing
Apr 18, 2008Auditor changeChange in certifying accountant (8-K Item 4.01)
Jan 26, 2007ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?